Table 1.
Characteristic | Deaths (n,%) | Age at years (mean ± SD) | Age at years (Median) | Age at years (Range) | CMR (/105) | ASMRW (/105) | YLL (years) | YLL rate (/105) |
---|---|---|---|---|---|---|---|---|
Gender | ||||||||
Male | 281 (54.14) | 65.46 ± 18.39 | 68.47 | 5.73-93.81 | 1.25 | 0.71 | 3604.24 | 16.01 |
Female | 238 (45.86) | 69.39 ± 18.71 | 75.16 | 12.62-94.19 | 1.05 | 0.52 | 2935.15 | 12.99 |
Periods | ||||||||
2005–2008 | 169 (32.56) | 61.11 ± 17.98 | 70.96 | 5.73-93.77 | 1.62 | 0.99 | 2216.12 | 21.27 |
2009–2012 | 137 (26.40) | 66.70 ± 19.19 | 73.92 | 13.87-92.49 | 1.24 | 0.68 | 1757.79 | 15.96 |
2013–2016 | 106 (20.42) | 66.57 ± 19.50 | 69.94 | 13.74-94.19 | 0.92 | 0.52 | 1346.94 | 11.69 |
2017–2020 | 107 (20.62) | 70.49 ± 17.90 | 73.31 | 13.74-93.42 | 0.88 | 0.38 | 1218.55 | 10.03 |
Metastatic cancer | ||||||||
All metastatic bone cancer | 129 (24.86) | 62.54 ± 20.78 | 67.35 | 12.62-94.19 | 0.29 | 0.19 | 1855.60 | 4.11 |
Metastatic bone cancer to the lung (C78.0) | 53 (10.21) | 57.38 ± 22.12 | 62.87 | 13.45-93.32 | 0.12 | 0.09 | 856.61 | 1.90 |
Metastatic bone cancer to the liver (C78.7) | 11 (2.12) | 64.36 ± 16.46 | 69.66 | 32.31-85.92 | 0.02 | 0.01 | 154.97 | 0.34 |
Metastatic bone cancer to the unknown sites | ||||||||
47 (9.06) | 66.13 ± 19.06 | 68.63 | 13.12-93.59 | 0.10 | 0.06 | 622.60 | 1.38 | |
(C79) The main comorbidity in all causes of death |
||||||||
Diseases of the respiratory system (J00–J99) | 77 (14.84) | 69.92 ± 17.92 | 72.61 | 13.45-93.54 | 0.17 | 0.08 | 880.54 | 1.95 |
Diseases of the circulatory system (I00–I99) | 25 (4.82) | 62.79 ± 23.42 | 73.66 | 13.12-90.99 | 0.06 | 0.04 | 350.40 | 0.78 |
Total bone cancer-specific death | 519 (100.00) | 67.26 ± 18.62 | 71.82 | 5.73-94.19 | 1.15 | 0.61 | 6539.39 | 14.50 |
Total all cause of death of the population | 336,823 (/) | 76.99 ± 14.44 | 80.45 | 0.00-116.39 | 746.71 | 279.39 | 3040514.99 | 6740.55 |
ASMRW, age-standardized mortality rate by Segi’s world standard population; CMR, crude mortality rate; YLL, years of life lost.